CoChat

Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-mediated Dystrophin Exon Skipping in Heart and Phenotypic Correction in mdx Mice

Open access
Yin, HaiFang, Saleh, Amer F, Betts, Corinne, Camelliti, Patrizia, Seow, Yiqi, Ashraf, Shirin, Arzumanov, Andrey, Hammond, Suzan, Merritt, Thomas, Gait, Michael J, Wood, Matthew JA · 2011 · Molecular Therapy
Cited by 135

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Induced splice modulation of pre-mRNAs shows promise to correct aberrant disease transcripts and restore functional protein and thus has therapeutic potential. Duchenne muscular dystrophy (DMD) results from mutations that disrupt the DMD gene open reading frame causing an absence of dystrophin protein. Antisense oligonucleotide (AO)-mediated exon skipping has been shown to restore functional dystrophin in mdx mice and DMD patients treated intramuscularly in two recent phase 1 clinical trials. Critical to the therapeutic success of AO-based treatment will be the ability to deliver AOs systemically to all affected tissues including the heart. Here, we report identification of a series of transduction peptides (Pip5) as AO conjugates for enhanced systemic and particularly cardiac delivery. One of the lead peptide-AO conjugates, Pip5e-AO, showed highly efficient exon skipping and dystrophin production in mdx mice with complete correction of the aberrant DMD transcript in heart, leading to >50% of the normal level of dystrophin in heart. Mechanistic studies indicated that the enhanced activity of Pip5e-phosphorodiamidate morpholino (PMO) is partly explained by more efficient nuclear delivery. Pip5 series derivatives therefore have significant potential for advancing the development of exon skipping therapies for DMD and may have application for enhanced cardiac delivery of other biotherapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2011.79

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Very mild muscular dystrophy associated with the deletion of 46% of dystrophin

    England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E. (1990) · Nature · doi:10.1038/343180a0 · Cited by 623 · cited 1×

    “Antisense oligonucleotide (AO)-mediated exon skipping can restore the open reading frame of mutant DMD pre-mRNA transcripts [3-15] and produce truncated but partially functional dystrophin protein [16-17].”
  • Systemic delivery of genes to striated muscles using adeno-associated viral vectors

    Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004) · Nature Medicine · doi:10.1038/nm1085 · Cited by 620 · cited 1×

    “Antisense oligonucleotide (AO)-mediated exon skipping can restore the open reading frame of mutant DMD pre-mRNA transcripts [3-15] and produce truncated but partially functional dystrophin protein [16-17].”

Show all 2 references

Cited by

See all 135

Metadata

Authors
Yin, H., Saleh, A. F., Betts, C., Camelliti, P., Seow, Y., Ashraf, S., Arzumanov, A., Hammond, S., Merritt, T., Gait, M. J., & Wood, M. J.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2011-07
Volume
19
Issue
7
Pages
1295-1303
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2004824383
Cited by
135
References
2
FWCI
5.76
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-mediated Dystrophin Exon Skipping in Heart and Phenotypic Correction in mdx Mice. https://app.cochat.ai/papers/10.1038/mt.2011.79
The paper
Yin, H., Saleh, A. F., Betts, C., Camelliti, P., Seow, Y., Ashraf, S., Arzumanov, A., Hammond, S., Merritt, T., Gait, M. J., & Wood, M. J. (2011). Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-mediated Dystrophin Exon Skipping in Heart and Phenotypic Correction in mdx Mice. Molecular Therapy. https://doi.org/10.1038/mt.2011.79

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.